Laser Focus World is an industry bedrock—first published in 1965 and still going strong. We publish original articles about cutting-edge advances in lasers, optics, photonics, sensors, and quantum technologies, as well as test and measurement, and the shift currently underway to usher in the photonic integrated circuits, optical interconnects, and copackaged electronics and photonics to deliver the speed and efficiency essential for data centers of the future.

Our 80,000 qualified print subscribers—and 130,000 12-month engaged online audience—trust us to dive in and provide original journalism you won’t find elsewhere covering key emerging areas such as laser-driven inertial confinement fusion, lasers in space, integrated photonics, chipscale lasers, LiDAR, metasurfaces, high-energy laser weaponry, photonic crystals, and quantum computing/sensors/communications. We cover the innovations driving these markets.

Laser Focus World is part of Endeavor Business Media, a division of EndeavorB2B.

Laser Focus World Membership

Never miss any articles, videos, podcasts, or webinars by signing up for membership access to Laser Focus World online. You can manage your preferences all in one place—and provide our editorial team with your valued feedback.

Magazine Subscription

Can you subscribe to receive our print issue for free? Yes, you sure can!

Newsletter Subscription

Laser Focus World newsletter subscription is free to qualified professionals:

The Daily Beam

Showcases the newest content from Laser Focus World, including photonics- and optics-based applications, components, research, and trends. (Daily)

Product Watch

The latest in products within the photonics industry. (9x per year)

Bio & Life Sciences Product Watch

The latest in products within the biophotonics industry. (4x per year)

Laser Processing Product Watch

The latest in products within the laser processing industry. (3x per year)

Get Published!

If you’d like to write an article for us, reach out with a short pitch to Sally Cole Johnson: [email protected]. We love to hear from you.

Photonics Hot List

Laser Focus World produces a video newscast that gives a peek into what’s happening in the world of photonics.

Following the Photons: A Photonics Podcast

Following the Photons: A Photonics Podcast dives deep into the fascinating world of photonics. Our weekly episodes feature interviews and discussions with industry and research experts, providing valuable perspectives on the issues, technologies, and trends shaping the photonics community.

Editorial Advisory Board

  • Professor Andrea M. Armani, University of Southern California
  • Ruti Ben-Shlomi, Ph.D., LightSolver
  • James Butler, Ph.D., Hamamatsu
  • Natalie Fardian-Melamed, Ph.D., Columbia University
  • Justin Sigley, Ph.D., AmeriCOM
  • Professor Birgit Stiller, Max Planck Institute for the Science of Light, and Leibniz University of Hannover
  • Professor Stephen Sweeney, University of Glasgow
  • Mohan Wang, Ph.D., University of Oxford
  • Professor Xuchen Wang, Harbin Engineering University
  • Professor Stefan Witte, Delft University of Technology

Dr. Michael Lim Ming Soon’s Cell Genesis Laboratories Announces a Pioneering Breakthrough with CEXCI Stem Cell Protein Therapy

Petaling Jaya, Selangor, Malaysia, 9th Sep 2023 – Under the esteemed guidance of Dr. Michael Lim Ming Soon, Cell Genesis Laboratories has unveiled a pioneering approach in regenerative medicine, harnessing the profound capabilities of CEXCI Proteins. The lab’s inventive procedures involve strategically priming these proteins, enhancing their capacity to promote more effective cell-to-cell communication. This groundbreaking methodology promises to reshape the landscape of therapeutic interventions, offering unparalleled precision and efficacy in addressing complex medical conditions. Dr. Lim’s visionary leadership positions Cell Genesis Laboratories at the forefront of stem cell research and therapy, exemplifying commitment to scientific excellence and patient-centric care.

Cell Preconditioning Methods: Enhancing Therapeutic Potential

A foundational element of the CEXCI therapeutic strategy championed by Dr. Michael Lim and his team revolves around the intricate preconditioning process of CEXCI Proteins in the laboratory. This process involves the exposure of these proteins to specific factors or conditions before transplantation. This scientifically robust procedure ensures the CEXCI Stem Cell Protein augmented therapeutic potential in the host body after transplantation.

Such innovations reflect Dr. Michael Lim’s unwavering commitment to elevating the success rate and effectiveness of CEXCI Proteins’ potential therapeutic effect, ensuring the most advanced care possible.

Revolutionizing Cell-to-Cell Communication with CEXCI Proteins

Central to Cell Genesis’s approach is the optimized design of CEXCI Proteins. These proteins have been specifically tailored to bolster cell-to-cell communication – a foundational process in multicellular organisms. CEXCI Proteins play a crucial role in directing the signalling pathways that facilitate cell-to-cell communication and their microenvironment. With this enhanced communication enables cells to better synchronize and coordinate their activities, which is vital for maintaining optimal health and initiating reparative mechanisms.

With the introduction of CEXCI Proteins, the equilibrium of these signaling pathways is well maintained and it holds the key to maintaining optimal tissue balance and enabling effective regeneration. When disrupted, these pathways can contribute to a range of conditions, from cancer to degenerative disorders. The in-depth exploration of these signalling mechanisms not only advances our understanding but also paves the way for unlocking the therapeutic potential of CEXCI Proteins in tackling ailments and facilitating tissue rejuvenation.

Conclusion

Dr Michael Lim Ming Soon’s Cell Genesis Laboratories, with its deep-rooted scientific expertise and innovative protocols, is setting new benchmarks in the realm of regenerative medicine. The lab’s commitment to refining and advancing the stem cell industry is evident in the innovative deployment of CEXCI Proteins.

Beyond mere treatment, these therapies embody a promise of holistic restoration by leveraging the body’s innate healing capacities. The advancements in cellular communication, driven by CEXCI Proteins, pave the way for a more integrated and harmonious cellular functionality, ensuring comprehensive healing and rejuvenation.

Cell Genesis Laboratories, under the esteemed guidance of Dr. Michael Lim Ming Soon, extends an invitation to the scientific community, stakeholders, and the wider public to engage with this transformative realm of CEXCI stem cell Proteins therapy. As we collectively forge ahead, our dedication to scientific excellence remains unwavering, aiming to convert research into real-world therapeutic solutions.

About Cell Genesis:

Cell Genesis, founded by Dr Michael Lim, is a leading biotechnology company dedicated to advancing the frontiers of science and medicine. They specialize in innovative research, development, and commercialization of cutting-edge technologies aimed at transforming healthcare and improving patient outcomes. With a strong focus on stem cell technology, they are committed to pushing boundaries, driving discoveries, and bringing revolutionary therapies to the forefront of modern medicine.

For more information, please visit the official website: https://cellgenesis.com.my/

Media Contact

Organization: Cell Genesis

Contact Person: Dr. Michael Lim Ming Soon

Website: https://cellgenesis.com.my/

Email: admin@cellgenesis.com.my

Contact Number: ‎+60 3-7622 2991

City: Petaling Jaya

State: Selangor

Country: Malaysia

Release Id: 0909236151

The post Dr. Michael Lim Ming Soon’s Cell Genesis Laboratories Announces a Pioneering Breakthrough with CEXCI Stem Cell Protein Therapy appeared first on King Newswire. It is provided by a third-party content provider. King Newswire makes no warranties or representations in connection with it.


Information contained on this page is provided by an independent third-party content provider. eTrendystock make no warranties or representations in connection therewith. If you are affiliated with this page and would like it removed please contact contact@etrendystock.com

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.